Significance of Bax Expression in Breast Cancer Patients

• Autorzy: Piotr Pluta , Piotr Smolewski , Agnieszka Pluta , Barbara Cebula-Obrzut , Agnieszka Wierzbowska , Dariusz Nejc , Tadeusz Robak , Radzisław Kordek , Leszek Gottwald , Janusz Piekarski , Arkadiusz Jeziorski
• Języki publikacji: EN

Abstrakty

EN

Bax protein, the proapoptotic member of Bcl-2 protein family, plays the key role in apoptosis pathway.The aim of the study was to assess the expression of Bax protein in breast cancer cells.Material and methods. Sixty-two breast cancer patients were included in the study. The control group encompassed 11 fibroadenoma patients. Single cells were isolated from defrosted samples and prepared for flow cytometry measurement.Results. Median expression of Bax protein in study group was 7.9% (range: 0-49.4%) and was significantly lower than in control (median expression 15.8%; range 4.9-30.9%; p=0.034). Expression of Bax correlated with expression of p53 and caspase-3 proteins (p<0,01, rank Spearman test). In patients under 70 years old and with positive estrogen receptors status the expression of Bax protein was significantly higher (p=0.03 and p=0.01 respectively).Conclusions. Lower expression of Bax protein in breast cancer cells may suggest the potential way of apoptosis avoidance of tumor cells. Correlations among Bax protein, p53 and caspase-3 are likely associated with active apoptotic mechanism in breast cancer cells expressing Bax protein. Further investigation with long time follow-up should be performed to establish the prognostic role of Bax protein expression in breast cancer patients.

Słowa kluczowe

EN

breast cancer; apoptosis; Bax protein

• Czasopismo: Polish Journal of Surgery
• Rocznik: 2011
• Tom: 83
• Numer: 10
• Strony: 549-553

Daty

wydano

2011-10-01

online

2011-12-21

Twórcy

autor

Piotr Pluta

• Department of Surgical Oncology, Medical University in Łódź

autor

Piotr Smolewski

• Department of Experimental Hematology, Medical University in Łódź

autor

Agnieszka Pluta

• Department of Hematology, Medical University in Łódź

autor

Barbara Cebula-Obrzut

• Department of Experimental Hematology, Medical University in Łódź

autor

Agnieszka Wierzbowska

• Department of Hematology, Medical University in Łódź

autor

Dariusz Nejc

• Department of Surgical Oncology, Medical University in Łódź

autor

Tadeusz Robak

• Department of Hematology, Medical University in Łódź

autor

Radzisław Kordek

• Department of Oncological Pathology, Medical University in Łódź

autor

Leszek Gottwald

• Palliative Medicine Unit, Medical University in Łódź

autor

Janusz Piekarski

• Department of Surgical Oncology, Medical University in Łódź

autor

Arkadiusz Jeziorski

• Department of Surgical Oncology, Medical University in Łódź

Bibliografia

• Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972 Aug; 26(4): 239-57.[Crossref]
• Adams JM, Huang DC, Puthalakath H et al.: Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 1999; 64: 351-58.
• Daidone MG, Luisi A, Veneroni S et al.: Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999 Mar; 6(1): 61-68.[Crossref]
• Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999 Aug 1; 13(15): 1899-1911.
• Sturm I, Köhne CH, Wolff G et al.: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999 May; 17(5): 1364-74.
• Sturm I, Petrowsky H, Volz R et al.: Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001 Apr 15; 19(8): 2272-81.
• Krajewski S, Blomqvist C, Franssila K et al.: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995 Oct 1; 55(19): 4471-78.[PubMed]
• Krajewski S, Thor AD, Edgerton SM et al.: Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997 Feb; 3(2): 199-208.
• Ehemann V, Sykora J, Vera-Delgado J et al.: Flow cytometric detection of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett 2003; 194: 125-31.
• Shibata MA, Liu ML, Knudson MC et al.: Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999 May 17; 18(10): 2692-2701.
• Zhang Yi-Li, Wu Sheng-Li, Du Hong-Weng et al.: Correlation of mammographical imaging signs with expression of Bcl-2 and Bax proteins in breast cancer. J Cancer Mol 2005; 1: 99-102.
• Veronese S, Mauri FA, Caffo O et al.: Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer 1998 Feb 20; 79(1): 13-18.[Crossref]
• Martínez-Arribas F, Martín-Garabato E, Zapardiel I et al.: Bax expression in untreated breast cancer: an immunocytometric study of 255 cases. Anticancer Res 2008 Sep-Oct; 28(5A): 2595-98.
• Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005 Oct; 16(10): 1569-83.[Crossref][PubMed][WoS]
• Kassam F, Enright K, Dent R et al.: Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009 Feb; 9(1): 29-33.[WoS][PubMed][Crossref]

Identyfikatory

DOI

10.2478/v10035-011-0087-4